scholarly journals Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment

Hepatology ◽  
2017 ◽  
Vol 66 (2) ◽  
pp. 389-397 ◽  
Author(s):  
Fred Poordad ◽  
Franco Felizarta ◽  
Armen Asatryan ◽  
Mark S. Sulkowski ◽  
Robert W. Reindollar ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Treatment ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Direct Acting Antiviral ◽  
Direct Acting

scholarly journals Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure

Hepatology ◽  
2018 ◽  
Vol 67 (4) ◽  
pp. 1253-1260 ◽  
Author(s):  
Fred Poordad ◽  
Stanislas Pol ◽  
Armen Asatryan ◽  
Maria Buti ◽  
David Shaw ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Treatment Failure ◽  
Antiviral Treatment ◽  
Genotype 1 ◽  
Virus Genotype ◽  
Direct Acting Antiviral ◽  
Direct Acting

scholarly journals Reassessment of Genotype 1 Hepatitis C Virus Subtype Misclassification by LiPA 2.0: Implications for Direct-Acting Antiviral Treatment

2014 ◽  
Vol 52 (11) ◽  
pp. 4027-4029 ◽  
Author(s):  
J. R. Guelfo ◽  
J. Macias ◽  
K. Neukam ◽  
F. A. Di Lello ◽  
J. A. Mira ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Antiviral Treatment ◽  
Genotype 1 ◽  
Direct Acting Antiviral ◽  
Direct Acting ◽  
Virus Subtype
Sign in / Sign up

Export Citation Format

Share Document